Fiduciary Alliance LLC Purchases New Position in Humana Inc. (NYSE:HUM)

Fiduciary Alliance LLC bought a new stake in shares of Humana Inc. (NYSE:HUM) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 5,418 shares of the insurance provider’s stock, valued at approximately $1,375,000.

Other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp boosted its position in shares of Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock valued at $1,701,582,000 after buying an additional 53,272 shares during the last quarter. FMR LLC lifted its stake in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Pzena Investment Management LLC boosted its holdings in shares of Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after acquiring an additional 187,903 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after acquiring an additional 774,085 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Humana by 2.1% during the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after purchasing an additional 24,842 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

HUM opened at $287.48 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market capitalization of $34.62 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 2.12 and a beta of 0.55. The company has a fifty day moving average of $273.89 and a 200 day moving average of $309.74. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $455.53.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. As a group, sell-side analysts forecast that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.23%. Humana’s dividend payout ratio is currently 31.36%.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.32% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on HUM shares. Oppenheimer decreased their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. KeyCorp assumed coverage on Humana in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. UBS Group lowered their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. Finally, Wells Fargo & Company cut their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $302.00.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.